- In September 2023, Elanco Animal Health Incorporated announced that the first shipments of Varenzin-CA1 (molidustat oral suspension), conditionally approved by the U.S. Food and Drug Administration (FDA) as the first and only treatment for controlling non-regenerative anemia in cats with chronic kidney disease (CKD), are now being distributed to veterinary clinics nationwide. Anemia caused by CKD can significantly impact a cat's quality of life, leading to symptoms such as lethargy, loss of appetite, and in severe cases, rapid heart rate and difficulty breathing.
- In August 2023, Boehringer Ingelheim announced the launch of NexGard (afoxolaner) S and M in India. This addition to the NexGard product line caters to small dogs (weighing 2-4 kg) and medium dogs (weighing 4-10 kg), following the successful introduction of NexGard X and L in 2020. NexGard is intended for use in dogs and puppies aged eight weeks and older, provided as a monthly treatment in highly palatable flavored chewables. It effectively kills fleas before they can lay eggs, as well as ticks and mites.
- In July 2023, Invetx announced the successful completion of the development of its species-specific, half-life extension technology for dogs and cats, resulting in a longer duration of activity for the company's veterinary monoclonal antibodies. This innovative technology allows the company to enhance antibody treatment options for chronic and severe diseases in pets. Invetx has been granted four U.S. patents for its half-life extension technology and has additional patents pending in the U.S., Europe, and other regions.
- In January 2022, Zoetis announced that the U.S. Food and Drug Administration (FDA) had approved a new label indication for Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) for the prevention of Borrelia burgdorferi infections caused by the killing of Ixodes scapularis (black-legged or deer) ticks. Simparica Trio is approved for dogs eight weeks of age and older, weighing 2.8 pounds or more. It is the first and only combination product shown to prevent infections that could lead to Lyme disease by eliminating deer or black-legged ticks.
- In September 2021, Invetx announced the launch of a clinical field study in dogs aimed at an undisclosed chronic condition, using IVX-01, its proprietary, novel, fully canine, high-affinity, and half-life extended monoclonal antibody (mAb).
